A double-blind, randomized, parallel group, placebo-controlled study to evaluate the safety and efficacy of NM 702 [parogrelil] in subjects with intermittent claudication
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2005
At a glance
- Drugs Parogrelil (Primary)
- Indications Arteriosclerosis obliterans; Embolism and thrombosis; Intermittent claudication
- Focus Therapeutic Use
- 30 Oct 2005 New trial record.